drugset

drugset / Trial / NCT00859053

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

NCT00859053 ↗

Phase 1 Completed 46 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.

Timeline

Start: 2009-03
Primary completion: 2009-09
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Daclatasvir	Small molecule	30 mg	Oral

Indications